menu
Several companies worldwide claim to possess the required expertise and infrastructure
Several companies worldwide claim to possess the required expertise and infrastructure
Several companies worldwide claim to possess the required expertise and infrastructure

Several companies worldwide claim to possess the required expertise and infrastructure

Althoughbiopharmaceuticals offer significant profit margins and have been proven to beeffective in treating a myriad of diseases, they are generally associated withhigh costs of development and complex manufacturing protocols; this is true forantibody-based products as well. Presently, there are a number of companiesthat claim to offer end-to-end solutions, ranging from antibody development tocommercial production. Further, prevalent trends suggest that sponsor companiesare likely to continue relying on contract service providers for variousaspects of antibody-based product development and manufacturing.

 

To order this 285+ page report, which features100+ figures and 110+ tables, please visit this link

 

The USD 17 billion (by 2030) financial opportunitywithin the antibody contract manufacturing market has been analyzed across thefollowing segments:

§ Type of Antibodies

§ Monoclonal Antibodies

§ Bispecific Antibodies

§ ADCs

§ Others

 

§ Company Size

§ Small

§ Mid-sized

§ Large / Very Large

 

§ Scale of Operation

§ Preclinical / Clinical

§ Commercial

 

§ Type of expressionsystem used

§ Mammalian

§ Microbial

 

§ Key geographicalregions

§ North America

§ Europe

§ Asia and RoW

 

TheAntibody Contract Manufacturing Market, 2020-2030 reportfeatures the following companies, which we identified to be key players in thisdomain: 

§ AGC Biologics

§ Aldevron

§ AMRI

§ Boehringer IngelheimBioXcellence

§ Emergent BioSolutions

§ Eurofins CDMO

§ FUJIFILM DiosynthBiotechnologies

§ KBI Biopharma

§ Lonza

§ Nitto Avecia PharmaServices

§ Novasep

§ Pierre Fabre

§ Samsung BioLogics

§ Synthon

§ Thermo FisherScientific

 

Table of Contents

 

1. Preface

 

2. Executive Summary

 

3. Introduction

 

4. Market Landscape

 

5. Company Competitive Analysis

 

6. Company Profiles

 

7. Case Study: Comparison ofSmall and Large Molecules (Biologics) Drugs / Therapies

 

8. Benchmark Analysis

 

9. Partnerships

 

10. Recent Expansions

 

11. Capacity Analysis

 

12. Demand Analysis

 

13. Market Sizing andOpportunity Analysis

 

14. SWOT Analysis

 

15. Future of The Antibody CMOMarket

 

16. Interview Transcripts

 

17. Appendix 1: List of AntibodyCustom Manufacturers

 

18. Appendix 2: Tabulated Data

 

19. Appendix 3: List ofCompanies and Organizations

Topurchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html

 

ContactDetails

GauravChaudhary

+1(415) 800 3415

gaurav.chaudhary@rootsanalysis.com